Gland Pharma has announced its audited financial results for the quarter and financial year ending 31 March 2026. The results, which include both standalone and consolidated figures, have been reviewed and recommended by the company’s Audit Committee.
The statutory auditors of Gland Pharma have issued audit reports with an unmodified opinion on the audited financial statements, indicating a clean and fair view of the company’s financial position. The results were prepared in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The announcement follows the company’s previous intimation dated 21 April 2026, regarding the board meeting notice. The board of directors considered and approved the financial results during their meeting held on 15 May 2026.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).